ALT
Price
$5.22
Change
-$0.23 (-4.22%)
Updated
Mar 11, 01:46 PM (EDT)
Capitalization
428.97M
58 days until earnings call
VRNA
Price
$61.95
Change
+$0.59 (+0.96%)
Updated
Mar 11, 03:42 PM (EDT)
Capitalization
5.29B
50 days until earnings call
Ad is loading...

ALT vs VRNA

Header iconALT vs VRNA Comparison
Open Charts ALT vs VRNABanner chart's image
Altimmune
Price$5.22
Change-$0.23 (-4.22%)
Volume$659
Capitalization428.97M
Verona Pharma
Price$61.95
Change+$0.59 (+0.96%)
Volume$200
Capitalization5.29B
ALT vs VRNA Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. VRNA commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and VRNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (ALT: $5.45 vs. VRNA: $61.29)
Brand notoriety: ALT and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 98% vs. VRNA: 106%
Market capitalization -- ALT: $428.97M vs. VRNA: $5.29B
ALT [@Biotechnology] is valued at $428.97M. VRNA’s [@Biotechnology] market capitalization is $5.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, VRNA is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 3 TA indicator(s) are bullish while VRNA’s TA Score has 3 bullish TA indicator(s).

  • ALT’s TA Score: 3 bullish, 5 bearish.
  • VRNA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both ALT and VRNA are a bad buy in the short-term.

Price Growth

ALT (@Biotechnology) experienced а -8.93% price change this week, while VRNA (@Biotechnology) price change was -7.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.68%. For the same industry, the average monthly price growth was -9.30%, and the average quarterly price growth was -8.75%.

Reported Earning Dates

ALT is expected to report earnings on May 08, 2025.

VRNA is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($5.29B) has a higher market cap than ALT($429M). VRNA YTD gains are higher at: 31.977 vs. ALT (-24.341). ALT has higher annual earnings (EBITDA): -103.19M vs. VRNA (-136.9M). VRNA has more cash in the bank: 336M vs. ALT (139M). ALT has less debt than VRNA: ALT (1.77M) vs VRNA (122M). VRNA has higher revenues than ALT: VRNA (5.62M) vs ALT (52K).
ALTVRNAALT / VRNA
Capitalization429M5.29B8%
EBITDA-103.19M-136.9M75%
Gain YTD-24.34131.977-76%
P/E RatioN/AN/A-
Revenue52K5.62M1%
Total Cash139M336M41%
Total Debt1.77M122M1%
FUNDAMENTALS RATINGS
ALT vs VRNA: Fundamental Ratings
ALT
VRNA
OUTLOOK RATING
1..100
6076
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
833
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
9191
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRNA's Valuation (84) in the Pharmaceuticals Other industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that VRNA’s stock grew similarly to ALT’s over the last 12 months.

VRNA's Profit vs Risk Rating (3) in the Pharmaceuticals Other industry is significantly better than the same rating for ALT (83) in the Miscellaneous Commercial Services industry. This means that VRNA’s stock grew significantly faster than ALT’s over the last 12 months.

VRNA's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as ALT (95) in the Miscellaneous Commercial Services industry. This means that VRNA’s stock grew similarly to ALT’s over the last 12 months.

VRNA's Price Growth Rating (91) in the Pharmaceuticals Other industry is in the same range as ALT (91) in the Miscellaneous Commercial Services industry. This means that VRNA’s stock grew similarly to ALT’s over the last 12 months.

VRNA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that VRNA’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTVRNA
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 12 days ago
85%
Bullish Trend 12 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCCGX22.74N/A
N/A
Fidelity Advisor Small Cap Growth C
BDFUX31.92N/A
N/A
Baron Discovery R6
BGRWX27.93N/A
N/A
Barrett Growth Retail
BUFTX22.58N/A
N/A
Buffalo Mid Cap Discovery
RWINX13.92-0.21
-1.49%
Redwood AlphaFactor Tactical Intl N

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with VKTX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
-2.06%
VKTX - ALT
41%
Loosely correlated
-3.92%
CLDX - ALT
40%
Loosely correlated
-5.37%
LYEL - ALT
39%
Loosely correlated
-7.98%
CCCC - ALT
39%
Loosely correlated
-8.90%
KROS - ALT
39%
Loosely correlated
-4.09%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with VCYT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
-5.20%
VCYT - VRNA
38%
Loosely correlated
-5.09%
TRDA - VRNA
34%
Loosely correlated
-2.23%
CLDX - VRNA
32%
Poorly correlated
-5.37%
ROIV - VRNA
31%
Poorly correlated
-0.56%
COGT - VRNA
31%
Poorly correlated
-2.00%
More